Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
RP Management, LLC (CIK 1507673) reported $138.8M across 4 reported positions in its SEC 13F filing for 2025-03-31. Largest positions: BHVN ($70.6M, 50.84%), CYTK ($39.4M, 28.38%), BCRX ($28.8M, 20.78%), VIRX ($74, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | BHVN | BIOHAVEN LTD | $70.6M | 50.84% | 2.9M | Hold |
| 2 | CYTK | CYTOKINETICS, INC | $39.4M | 28.38% | 980,392 | Hold |
| 3 | BCRX | BIOCRYST PHARMACEUTICALS INC | $28.8M | 20.78% | 3.8M | Hold |
| 4 | VIRX | VIRACTA THERAPEUTICS INC | $74 | 0.00% | 3,700 | Hold |
Source: SEC Form 13F filings · as of 2025-03-31